Poststroke Epilepsy Risk Varies With Antihypertensive Treatment
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 17, 2024 -- For patients with hypertension and ischemic stroke, the risk for poststroke epilepsy (PSE) varies according to antihypertensive treatment, according to a study presented at the annual meeting of the American Epilepsy Society, held from Dec. 6 to 10 in Los Angeles.
Giacomo Evangelista, M.D., Ph.D., from the "G. d'Annunzio" University of Chieti-Pescara in Italy, and colleagues examined the effectiveness of antihypertensive treatment in preventing PSE in a retrospective, observational study. Patients with hypertension and diagnosis of ischemic stroke were retrospectively selected; all participants were followed up for PSE at a mean of 66 months.
The researchers found that 38 of the 528 patients (7.2 percent) developed PSE. The risk for PSE development was higher in association with anterior cerebral artery involvement and cortico-sottocortical lesions. The risk for PSE was lower in patients treated with angiotensin receptor blockers, while incidence was higher for those receiving calcium channel blockers and beta-blockers. No differences were seen for angiotensin-converting enzyme inhibitor use.
"These findings highlight the importance of personalized medicine, particularly in managing blood pressure in stroke patients," co-lead author Fedele Dono, M.D., also from G. d'Annunzio University of Chieti-Pescara, said in a statement. "Further research in more patients is necessary to confirm these findings and explore the underlying mechanisms in more detail."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
No Benefit Seen for Revascularization Added to Drug Therapy in Carotid Stenosis
FRIDAY, May 2, 2025 -- For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted stroke risk, there is no...
Hypertensive Disorders of Pregnancy Adversely Affect Preemie Neurodevelopment
THURSDAY, May 1, 2025 -- Maternal hypertensive disorders of pregnancy (HDP) are associated with adverse cognitive and language development in preterm infants at 2 years' corrected...
Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.